by Raynovich Rod | Oct 21, 2019 | Biopharmaceuticals, Clinical Diagnostics and Tools
Update-1 10/22. Some follow through in biotech rally but sold off mirroring the NASDAQ about 2p,Maybe BREXIT related but we’ll see later this week after many earnings reports. Large caps have been leading and although the IBB was up 1.66% it sold off from $107...
by Raynovich Rod | Oct 15, 2019 | Biopharmaceuticals, Macro
Update-1 Large caps were mixed but our top picks are doing well: ABBV,BMY,MRK,RHHBY. But bad news from JNJ and BA may have curbed buyer’s sentiment. United Health (UNH) off Mondays lows of $220 to $245. In summary it looks like a good time fo adding larger cap...
by Raynovich Rod | Oct 10, 2019 | Biopharmaceuticals
Update-2 10/13…Biotech IPOs Remain Weak-Recent rally was weak for small cap biotechs Vir Biotechnology (VIR): A clinical stage immunology and infectious disease Company focused on new therapies for hepatitis (HBV), Influenza A, HIV and TB went public on Friday....
by Raynovich Rod | Aug 19, 2019 | Biopharmaceuticals, Clinical Diagnostics and Tools, Macro
Update -3 Bearish trends in biopharma continue with both the IBB and XBI down with 30 min of trading to go. We will do a review of the healthcare sector later this week continuing the theme after the AACC of the need for diversification within healthcare e.g. medtech,...
by Raynovich Rod | Jul 11, 2019 | Biopharmaceuticals
Update-1 11a EDT, Large cap drugs and biotechs resume slide on drug pricing “reform” from Trump threats. IBB down 1.37%, XPH in downtrend tp $38.41. Laggards holding BIB, GILD. Winners losing MRK, RHHBY. LLY and PFE hit hard. Gene therapy green: BOLD,SGMO....
by Raynovich Rod | Jun 17, 2019 | Biopharmaceuticals
Update-3. Red screen day, post after close, macro intervening again. BMY/CELG delayed on Otezla divestiture. Update -2 …Week Ending 6/21-Biotech stocks up for the week but momentum easing. XBI up 1.2% to $87.26, off Wednesday highs. IBB up .2.2% to $109.45 QQQ...
by Raynovich Rod | Jun 10, 2019 | Biopharmaceuticals, Macro
Update-3 6/17 11:30 a EDT Pfizer (PFE) $11B Buyout of Array Pharmaceuticals (ARRY) Sparks Rally in biotech. As usual M&A brings buyers into biotech. ARRY up 56% on Pfizer $11B buyout. XBI up 3.68% to $84.46. Green screen in mid-caps, gene therapy. ==========...
by Raynovich Rod | Apr 30, 2019 | Biopharmaceuticals
Biopharma Wrap-Up: Sideways to Neutral in Active Trading for Quarter Biopharma stocks ended the quarter in a snooze as investors took a wait and see attitude as earnings roll-out for large caps. The IBB was off 0.83% today to $106.42 and up 9% QTD. The XBI is still up...
by Raynovich Rod | Feb 25, 2019 | Biopharmaceuticals, Clinical Diagnostics and Tools
Update: 1:40 EST 2/25… Gene Therapy stocks soar on Spark (ONCE) Deal: BLUE, CRSP, RARE; and XBI up 4.2%. Another big deal as GE sells healthcare business to Danher (DHR) for $21.4B; GE up 8.26%, DHR up 8.38%. ========== M&A Drives Mid and Small Cap Biotechs...
by Raynovich Rod | Feb 10, 2019 | Biopharmaceuticals
Biotech Stocks Hold Despite Last Thursday’s Sell-Off All in the Technicals For Now, Large Caps Look Steady Biotech ETFs lost momentum last week but held near term support near the 20 Day moving average. Now that most companies have reported we should not expect...